1. A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C. Issue 11 (10th October 2022) Authors: Chen, Chi‐Yi; Chuang, Wan‐Long; Qin, Albert; Zhang, Wen‐Hua; Zhu, Li‐Ying; Zhang, Guo‐Qiang; Chen, Jyh‐Jou; Lo, Ching‐Chu; Zhou, Xinmin; Mao, Xiaorong; Shang, Jia; Kuo, Hsing‐Tao; Xie, Wen; Chen, Chien‐Hung; Lo, Gin‐Ho; Jun, Dae W; Dang, Shuangsuo; Tsai, Chan‐Yen; Wang, Ting‐Fang; Lai, Hsin‐Hui Journal: JGH open Issue: Volume 6:Issue 11(2022) Page Start: 782 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Issue 5 (28th December 2021) Authors: Huang, Yi‐Wen; Qin, Albert; Fang, Jane; Wang, Ting‐Fang; Tsai, Chung‐Wei; Lin, Ko‐Chung; Teng, Ching‐Leou; Larouche, Richard Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 5(2022) Page Start: 2396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗